Ordering for 2019/2020 Is Simple and Flexible

Prebook FLUMIST QUADRIVALENT. Some patients may prefer an alternative to an injection.

Discount and Rebate Details. See terms and conditions; some restrictions apply.

Prebook by March 31, 2019, to receive 5% off list price of $22.95* per dose and $229.50 per package

  • Up to 25% of product purchased through March 31, 2020, may be eligible for return

  • Additional savings are available for accounts that prebook ≥400 doses. See the table below to determine discount based on the number of doses prebooked

FluMist® Quadrivalent discounts and flexible returns FluMist® Quadrivalent discounts and flexible returns

*Note: Net price based on list price of $22.95 per dose and $229.50 per package. Excise tax of $0.75 not included. Additional Distributor fees may apply.

Additional savings will be applied in the form of a rebate.

10 doses per package.

§Discounted prices (after rebate is applied) above are rounded to the nearest hundredth.

Ordering is easy!

Online, phone, or fax...you decide.

DISTRIBUTORS

TERMS AND CONDITIONS

FLUMIST QUADRIVALENT Prebook Program for 2019/2020

Eligible Customers

  • The 2019/2020 market offer is available to all customers not otherwise on an existing contract

Qualification for Discounts

  • Orders placed on or before March 31, 2019 will be eligible for a 5% discount off List Price
  • Orders must be in full pack quantities

Rebates

  • To qualify for up to 10% rebate off list price:
    • Prebook must be placed by March 31, 2019
    • 85% of prebook volume must be delivered and accepted by December 31, 2019
    • Rebate tier based on volume prebooked by Parent Account by March 31, 2019
    • Rebate volume based on net purchases made by Parent Account by March 31, 2020
    • Rebate earned will be calculated as (Qty Purchased – Qty Returned) x List Price x Rebate Rate
    • Reorders cannot increase tier, but returns can decrease tier
    • Rebates will be administered by Distributors in the form of credits applied to accounts by June 30, 2020

Returns

  • Accounts may return up to 25% of product purchased as long as they are prebooked by March 31, 2019 and accepted 85% of the prebooked volume by December 31, 2019
  • Returns must be in full pack quantities only; partial returns will be rounded down to the nearest full pack
  • The minimum purchase required for return eligibility is 40 doses
  • Returns must be sent back to authorized Distributors no later than March 31, 2020
  • For each valid return, customers will receive a refund of 100% of the net price paid in the form of a credit
  • Refunds for returns will be issued by authorized Distributors in the form of credits to customer accounts by June 30, 2020
x
Additional offers may be available through your Physician Buying Group or Group Purchasing Organization.

Contact your administrator about 2019-2020 pricing.

Important Safety Information

  • FLUMIST QUADRIVALENT is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy

  • In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist

  • Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FLUMIST QUADRIVALENT administration. FLUMIST QUADRIVALENT has not been studied in persons with severe asthma or active wheezing

  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST QUADRIVALENT should be based on careful consideration of the potential benefits and risks

  • FLUMIST QUADRIVALENT has not been studied in immunocompromised persons

  • The safety of FLUMIST QUADRIVALENT in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established

  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine

  • FLUMIST QUADRIVALENT may not protect all individuals receiving the vaccine

  • The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported were runny nose or nasal congestion in persons 2-49 years, fever >100°F in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FLUMIST QUADRIVALENT, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18-49 years who received FLUMIST QUADRIVALENT, 44% reported runny nose or nasal congestion and 19% reported sore throat

INDICATION

FLUMIST QUADRIVALENT is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUMIST QUADRIVALENT is for intranasal administration only.

Please see full Prescribing Information for FLUMIST QUADRIVALENT, including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.